Lumos Pharma, Inc. financial data

Location
4200 Marathon Blvd., Suite 200, Austin, TX
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 7, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 462 % -52.8%
Debt-to-equity 79.4 % +211%
Return On Assets -130 % -138%
Operating Margin -1.65K % +19.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 8.65M shares +9.27%
Common Stock, Shares, Outstanding 8.65M shares +9.27%
Entity Public Float 21.5M USD -53.7%
Weighted Average Number of Shares Outstanding, Basic 8.33M shares +4.38%
Weighted Average Number of Shares Outstanding, Diluted 8.33M shares +4.38%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 2.21M USD +26.9%
Revenue from Contract with Customer, Excluding Assessed Tax 2.21M USD +26.9%
Research and Development Expense 22.7M USD +11.8%
General and Administrative Expense 15.8M USD -6.13%
Operating Income (Loss) -36.3M USD -2.49%
Nonoperating Income (Expense) 1.41M USD -45.2%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -7.47M USD +10%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -34.9M USD -6.37%
Earnings Per Share, Basic -4 USD/shares -6.73%
Earnings Per Share, Diluted -4 USD/shares -6.73%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 13.5M USD -62%
Cash, Cash Equivalents, and Short-term Investments 36.1M USD -46.4%
Assets, Current 17.3M USD -63.6%
Property, Plant and Equipment, Net 0 USD -100%
Operating Lease, Right-of-Use Asset 187K USD -30.2%
Assets 17.5M USD -63.4%
Accounts Payable, Current 1.46M USD +198%
Employee-related Liabilities, Current 2.9M USD +3.14%
Accrued Liabilities, Current 4.92M USD -10.6%
Liabilities, Current 6.51M USD +6.36%
Operating Lease, Liability, Noncurrent 42K USD -70.6%
Liabilities 12.5M USD +2.35%
Accumulated Other Comprehensive Income (Loss), Net of Tax 0 USD
Retained Earnings (Accumulated Deficit) -187M USD -23%
Stockholders' Equity Attributable to Parent 4.91M USD -86.2%
Liabilities and Equity 17.5M USD -63.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -12.9M USD -40.2%
Net Cash Provided by (Used in) Financing Activities -5K USD +98.4%
Net Cash Provided by (Used in) Investing Activities 1M USD
Common Stock, Shares Authorized 75M shares 0%
Common Stock, Shares, Issued 8.68M shares +9.34%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -11.9M USD +0.59%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 13.5M USD -62%
Deferred Tax Assets, Valuation Allowance 133M USD +9.52%
Deferred Tax Assets, Gross 133M USD +9.52%
Operating Lease, Liability 585K USD +151%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -34.9M USD -6.35%
Lessee, Operating Lease, Liability, to be Paid 652K USD +176%
Operating Lease, Liability, Current 130K USD +3.18%
Lessee, Operating Lease, Liability, to be Paid, Year Two 303K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 332K USD +40.7%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure +233%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 67K USD +2133%
Lessee, Operating Lease, Liability, to be Paid, Year Three 17K USD
Deferred Tax Assets, Operating Loss Carryforwards 39M USD +10.8%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Additional Paid in Capital 192M USD +2.32%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 2K USD -77.8%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 1.87M USD -21.6%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%